Dopamine/serotonin receptor ligands. Part IV [1]: Synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands

Archiv der Pharmazie

Volumn 335, Issue 9, 2002, Pages 443-448

  El Subbagh, Hussein ^a,b   Wittig, Thomas ^b   Decker, Michael ^b   Elz, Sigurd ^c   Nieger, Martin ^d   Lehmann, Jochen ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

3 Benzazecine; 3 Benzazonine; 5 HT2A ligand; Dopamine receptor ligand; LE 300

Indexed keywords

3 BENZAZECINE DERIVATIVE; 3 BENZAZONINE DERIVATIVE; AMINE; AMMONIA; AROMATIC COMPOUND; AZEPINE DERIVATIVE; BENZENE; BUTYRIC ACID DERIVATIVE; CHLORIDE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; INDOLE; INDOLIZINE DERIVATIVE; KETANSERIN; LACTAM; LE 300; LIGAND; METHYL IODIDE; PHENETHYLAMINE; PHOSPHORUS DERIVATIVE; QUINOLIZINE DERIVATIVE; SEROTONIN 2A ANTAGONIST; SODIUM; SODIUM BOROHYDRIDE; UNCLASSIFIED DRUG; VALERIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BINDING AFFINITY; CATALYSIS; CHEMICAL BOND; CONTROLLED STUDY; CYCLIZATION; DRUG ACTIVITY; DRUG SYNTHESIS; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RADIOASSAY; RAT; REDUCTION; X RAY ANALYSIS;

ANIMALS; AZO COMPOUNDS; CHO CELLS; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; DOPAMINE ANTAGONISTS; HUMANS; INDOLES; LIGANDS; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; TAIL; VASOCONSTRICTION;

EID: 0036862092     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4184(200212)335:9<443::AID-ARDP443>3.0.CO;2-U     Document Type: Article

References (18)

1. Part III: A. H. Abadi, S. Lankow, B. Höfgen, M. Decker, M. U. Kassack, J. Lehmann, Arch. Pharm. Pharm. Med. Chem. 2002, 335, 367-373.
2. E. Zifa, G. Fillion, Pharmacol. Rev. 1992, 44, 401-457.
3. L. J. Siever, R. S. Khan, B. A. Lawlor, R. L. Trestman, T. L. Lawrence, E. F. Corraco, Pharmacol. Rev. 1991, 43, 509-525.
4. D. Hoyer, D. E. Clarke, J. R. Fozard, P. R. Hartig, G. R. Martin, E. J. Mylecharane, R R. Saxena, R R A. Humphrey, Pharmacol. Rev. 1994, 46, 157-203.
5. H. Anderson, B. Nielsen, Antipsychotics. DN&P 1991, 4, 150-157.
6. R Sokoloff, B. Giros, M. Martres, M. Bouthenet, J. Schwartz, Nature 1990, 347, 146-151.
7. H. VanTol, J. Bunzow, H. Guan, R. Sunahara, P. Seemann, H. Niznik, O. Civelli, Nature 1991, 350, 610-614.
8. H. Hara, M. Osakabe, A. Kitajima, Y. Tamao, R. Kikumoto, Thromb. Haemost. 1991, 65, 415-420.
9. T. Witt, F. J. Hock, J. Lehmann, J. Med. Chem. 2000, 43, 2079-2081.
10. S. A. F. Rostom, A. M. Farghaly, F. S. G. Solimann, M. M. El-Semary, S. Elz, J. Lehmann, Arch. Pharm. Pharm. Med. Chem. 2001, 334, 241-247.
11. K. Wiesner, Z. Valenta, A. J. Manson, F. W. Stonner, J. Am. Chem. Soc. 1955, 77, 675-83.
12. J. B. Bremner, K. N. Winzenberg, Austr. J. Chem. 1984, 37, 1203-15.
13. J. B. Bremner, K. N. Winzenberg, Austr. J. Chem. 1985, 38, 1591-612.
14. J. Lehmann, M. Nieger, T. Witt, Heterocycles 1994, 38, 511-528.
15. J. Mierau, F. J. Schneider, H. A. Ensinger, C. L. Chio, M. E. Lajiness, R. M. Huff, Mol. Pharmacol. 1995, 290, 29-36.
16. H. Pertz, S. Elz, J. Pharm. Pharmacol. 1995, 47, 310-316.
17. R. F. Furchgott in Catecholamines, Handbook of Experimental Pharmacology, Vol. 33 (Eds.: H. Blaschko, E. Muscholl), Springer-Verlag, Berlin, 1972, 283-335.
18. O. Arunlakshana, H. O. Schild, Br. J. Pharmacol. Chemother. 1959, 14, 48-58.